Literature DB >> 24675802

Hormone dependency in metastatic low-grade leiomyosarcoma following uterine smooth muscle tumour of uncertain malignant potential.

Cesar Serrano1, Marisa R Nucci, Sree H Tirumani, Chandrajit P Raut, Suzanne George.   

Abstract

Uterine leiomyosarcoma (ULMS) usually follows an aggressive clinical course, although a small proportion of ULMS exhibit a more indolent course, which in turn reflects heterogeneity within this disease and the need to identify and characterise this distinct subgroup. The role of hormone therapy in ULMS is yet to be elucidated. We report a patient with well-differentiated metastatic ULMS on hormone replacement therapy (HRT) at the time of the diagnosis. The withdrawal of the HRT led to a significant decrease in the tumour burden and symptomatic improvement. The patient further benefited from aromatase inhibitor treatment once the benefit from the HRT withdrawal reached a plateau. The present case report describes for the first time hormone-dependency for tumour growth in a ULMS. We propose that a subset of ULMS that follow a protracted/indolent course might depend on hormone stimulation for tumour proliferation, and antihormone treatment can therefore be useful in these patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24675802      PMCID: PMC3975512          DOI: 10.1136/bcr-2013-202107

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.

Authors:  Mario M Leitao; Martee L Hensley; Richard R Barakat; Carol Aghajanian; Ginger J Gardner; Elizabeth L Jewell; Roisin O'Cearbhaill; Robert A Soslow
Journal:  Gynecol Oncol       Date:  2011-11-13       Impact factor: 5.482

2.  "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.

Authors:  Emanuela Veras; Oliver Zivanovic; Lindsay Jacks; Daniel Chiappetta; Martee Hensley; Robert Soslow
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

3.  Use of estradiol-progestin therapy associates with increased risk for uterine sarcomas.

Authors:  Susanna Jaakkola; Heli K Lyytinen; Eero Pukkala; Olavi Ylikorkala
Journal:  Gynecol Oncol       Date:  2011-04-30       Impact factor: 5.482

Review 4.  Clinical management of uterine sarcomas.

Authors:  Frédéric Amant; An Coosemans; Maria Debiec-Rychter; Dirk Timmerman; Ignace Vergote
Journal:  Lancet Oncol       Date:  2009-12       Impact factor: 41.316

5.  Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases.

Authors:  S W Bell; R L Kempson; M R Hendrickson
Journal:  Am J Surg Pathol       Date:  1994-06       Impact factor: 6.394

6.  Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.

Authors:  Roisin O'Cearbhaill; Qin Zhou; Alexia Iasonos; Robert A Soslow; Mario M Leitao; Carol Aghajanian; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2009-11-24       Impact factor: 5.482

7.  Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen.

Authors:  E G Silva; C S Tornos; M Follen-Mitchell
Journal:  Int J Gynecol Pathol       Date:  1994-07       Impact factor: 2.762

8.  Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.

Authors:  Chandrajit P Raut; Marisa R Nucci; Qian Wang; Judith Manola; Monica M Bertagnolli; George D Demetri; Jeffrey A Morgan; Michael G Muto; Christopher D M Fletcher; Suzanne George
Journal:  Eur J Cancer       Date:  2009-07-31       Impact factor: 9.162

9.  Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis.

Authors:  Saketh R Guntupalli; Pedro T Ramirez; Matthew L Anderson; Michael R Milam; Diane C Bodurka; Anais Malpica
Journal:  Gynecol Oncol       Date:  2009-04-02       Impact factor: 5.482

10.  Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.

Authors:  Daniel S Kapp; Jacob Y Shin; John K Chan
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

  10 in total
  1 in total

1.  Secondary Leiomyosarcoma of the Lower Limb Following Uterine Smooth Muscle Tumor of Uncertain Malignant Potential.

Authors:  Jose María García-Sánchez; Mónica Bauza; Alberto Pérez-García; Empar Mayordomo Aranda; Alejandro Ruiz Valls
Journal:  Clin Med Insights Case Rep       Date:  2019-06-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.